Asia-Pacific Cancer Therapy Market Size

Statistics for the 2023 & 2024 Asia-Pacific Cancer Therapy market size, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Cancer Therapy size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Asia-Pacific Cancer Therapy Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
asia pacific cancer biological therapy market size
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 10.20 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

APAC Cancer Therapies Market Analysis

The Asia-Pacific cancer therapy market is expected to register a CAGR of 10.2% over the forecast period.

The COVID-19 pandemic disrupted routine care in many healthcare facilities and had an impact on healthcare systems all around the world, putting susceptible cancer patients in serious danger. The strict lockdowns and government regulations intended to slow down the spread of COVID-19 resulted in a decrease in therapy options for cancer patients. For instance, as per the study titled "Challenges and opportunities for ovarian cancer management in the epidemic of Covid-19: lessons learned from Wuhan, China" published in February 2021, treatment cancellation and delayed surgeries were challenging decisions. Ovarian cancer was identified as gynecologic cancer most affected by COVID-19, perhaps because of the frequent requirement for chemotherapy and ovarian debulking surgery. As a result, the pandemic might hurt the market. However, due to the rise in the incidence of cancers in the general population and fewer COVID-19 cases in the later stages of the pandemic, the market for treatments for cancer saw a noticeable increase in growth.

The Asia-Pacific cancer therapy market is expected to observe good growth owing to the rising prevalence of cancer, growing government initiatives for cancer awareness, and increasing patient assistance programs (PAPs). Lung, stomach, colorectum, liver, and esophagus are the most common types of cancer in Asia-Pacific region. For instance, as per the study titled "Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program" published in May 2022, the projected cancer burden in India for 2021 was 26.7 million Disability Adjusted Life Years (DALYs) and expected to increase to 29.8 million in 2025. Thus, the rising burden of cancers, helps the market to grow over the forecast period.

Furthermore, the advancements in the treatment of cancers with latest product approvals and launches drives the growth of the market. For instance, in August 2022, AstraZeneca India has received a Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer. Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

However, the high cost of cancer therapies and fluctuation in reimbursement policies is likely to impede the market's growth.

Asia-Pacific Cancer Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)